Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The newer macrolides: azithromycin and clarithromycin.

J M Zuckerman1

  • 1Department of Medicine, Temple University School of Medicine, Philadelphia, Pennsylvania, USA. Zukermj@aehn2.einstein.edu

Infectious Disease Clinics of North America
|June 1, 2000
PubMed
Summary

Azithromycin and clarithromycin are novel macrolide antibiotics offering advantages over erythromycin. This review covers their pharmacokinetics, antimicrobial activity, clinical applications, and side effects.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

FDA regulation of medical software.

Journal of health law·2000
Same author

The newer macrolides. Azithromycin and clarithromycin.

Infectious disease clinics of North America·1995
Same author

Itraconazole: a new triazole antifungal agent.

Infection control and hospital epidemiology·1994
Same author

Quantitative recovery, selective removal and one-step purification of human parotid and leukemic lysozymes by immunoadsorption.

European journal of biochemistry·1982
Same author

Fluorescence quantitation of s-IgA in parotid saliva and of s-IgA bound to oral microorganisms.

Advances in experimental medicine and biology·1978

Area of Science:

  • Pharmacology
  • Microbiology
  • Infectious Diseases

Background:

  • Azithromycin and clarithromycin are newer macrolide antimicrobial agents.
  • They are structural analogues of erythromycin.
  • These agents present distinct advantages compared to erythromycin.

Purpose of the Study:

  • To review the pharmacokinetics of azithromycin and clarithromycin.
  • To summarize the antimicrobial activity of these macrolides.
  • To discuss the clinical use and adverse effects of azithromycin and clarithromycin.

Main Methods:

  • Literature review of pharmacokinetic data.
  • Analysis of in vitro antimicrobial activity studies.
  • Synthesis of clinical trial data and post-marketing surveillance for adverse effects.

Related Experiment Videos

Main Results:

  • Azithromycin and clarithromycin exhibit favorable pharmacokinetic profiles, including enhanced tissue penetration and longer half-lives compared to erythromycin.
  • Both agents demonstrate broad-spectrum activity against common respiratory and skin pathogens.
  • Clinical studies show efficacy in treating various infections, with generally well-tolerated safety profiles, though specific adverse effects are noted.

Conclusions:

  • Azithromycin and clarithromycin represent significant advancements in macrolide antibiotic therapy.
  • Their distinct pharmacokinetic and antimicrobial properties support their widespread clinical utility.
  • Understanding their profiles is crucial for effective antimicrobial stewardship and patient management.